ZHZiyad M. Hijazi

Ziyad M. Hijazi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ziyad M. Hijazi has a total of 225 co-authors. Here are the top co-authors by number of shared publications:

  • Qi‐Ling Cao

    Section of Pediatric Cardiology, Department of Pediatrics, University of Chicago Hospitals, Chicago, Illinois

    13 shared publications
  • Qi-Ling Cao

    Departments of Pediatrics and

    9 shared publications
  • David J. Waight

    University of Chicago Children's Hospital and Pritzker School of Medicine, Chicago, Illinois, U.S.A.

    6 shared publications
  • Ralf Holzer

    Section of Cardiology, Department of Pediatrics, University of Chicago Comer Children's Hospital, Pritzker School of Medicine, Chicago, Illinois, USA

    6 shared publications
  • Jonathan Rhodes

    Division of Pediatric Cardiology, Floating Hospital for Children at New England Medical Center, Tufts University School of Medicine, Boston, Massachusetts

    5 shared publications
  • Mary Heitschmidt

    Section of Pediatric Cardiology, Department of Pediatrics, University of Chicago Children's Hospital and Pritzker School of Medicine, Chicago, Illinois

    5 shared publications

Latest Publications

  • List of Contributors

    by Iki Adachi, Jyothsna Akam-Venkata, Christopher S. Almond, Jeffrey B. Anderson, Jean Ballweg, Neha Bansal, Christine Benhase, Daniel Bernstein, Elizabeth D. Blume, Luke J. Burchill, et al.

  • Transcatheter pulmonary valve replacement: State of the art

    by Ralf J. Holzer, Ziyad M. Hijazi

    The number of patients undergoing transcatheter pulmonary valve replacement has been steadily increasing, resulting in many research projects focusing on this patient population. This has highlighted the need to summarize the currently available data. A review of the literature was conducted and the results summarized. At present, the two commercially available valves approved for transcatheter pulmonary valve replacement include the Edwards Sapien valve and the Medtronic Melody valve. More data has been published relating to the Melody valve; this included the incidence of coronary anatomy prohibiting valve implantation of 5%, an incidence of conduit disruption of 6%, and freedom from stent fracture of the Melody valve stent of 60% at 30 months. Short and medium term outcomes seem to be comparable if not superior to surgical valve replacement, but long-term data is still lacking. There may also be a cost benefit with transcatheter valve implantation when compared to surgical pulmonary valve replacement. Transcatheter pulmonary valve replacement is here to stay. The main challenge of treating patients with a native right ventricular outflow tract still needs to be addressed and device development efforts centered in this area.


  • Multisociety (AATS, ACCF, SCAI, and STS) Expert Consensus Statement: Operator and Institutional Requirements for Transcatheter Valve Repair and Replacement, Part 1: Transcatheter Aortic Valve Replacement

    by Carl L. Tommaso, R. Morton Bolman, Ted Feldman, Joseph Bavaria, Michael A. Acker, Gabriel Aldea, Duke E. Cameron, Larry S. Dean, Dave Fullerton, Ziyad M. Hijazi, et al.


  • Multiple Amplatzer septal occluder devices for multiple atrial communications: Immediate and long‐term follow‐up results

    by Sawsan M. Awad, Francisco F. Garay, Qi‐Ling Cao, Ziyad M. Hijazi

    Objectives: We report on the feasibility, effectiveness, and long‐term outcome of transcatheter closure of multiple ASD's using multiple ASO devices. Background: Little is known about the use and long‐term outcome of multiple Amplatzer Septal Occluder (ASO) devices to close multiple atrial septal defects (ASD's). Methods: From May 1997 to June 2006, 33 patients (mean age 38.9 years and mean weight 68 kg) underwent transcatheter closure of multiple ASD's under transesophageal (TEE) or intracardiac echocardiographic (ICE) guidance. Results: Unless not available, the device size chosen to be deployed was ±2 mm larger than the stretched diameter or no more than 30–40% larger than the ICE/TEE 2D diameter. Sixty‐seven devices were deployed in 33 patients. The mean diameters of the larger and smaller defects were 12.9 and 7.7 mm, and the corresponding mean balloon stretched diameters were 19.2 and 12.0 mm, respectively. The mean larger and smaller device diameters were 19.0 and 13.4 mm, respectively. The mean QP: Qs ratio was 1.8:1. The mean fluoroscopy time, and procedure time were 16.4 and 81.6 min respectively. Immediately after the procedure 15 patients had complete closure, 8 had trivial shunt, 9 had small shunt and one had large shunt. Complications included a device embolization within 24 hr and left atrial‐aortic wall erosion and pericardial effusion at 2 years. The mean follow‐up interval was 34.8 + 25.7 months. Conclusions: Device closure of multiple ASD's using multiple ASO's is safe and effective. Continued follow‐up is important to assess the long‐term outcome.


  • Device closure of muscular ventricular septal defects in infants less than one year of age using the Amplatzer devices: Feasibility and outcome

    by Karim A. Diab, Qi‐ Ling Cao, Bassem N. Mora, Ziyad M. Hijazi

    Objectives: In this study, we evaluated the feasibility, safety, and outcome of device closure of muscular ventricular septal defects (mVSD) in infants less than 1 year of age using the Amplatzer devices. Background: Closure of mVSDs continues to represent a surgical challenge with significant morbidity. Hence, device closure is becoming an attractive and reliable alternative. However, little is known about the feasibility of this procedure in small infants. Methods: Between July 1999 and September 2006, device closure of mVSD was attempted in 20 infants ranging in age from 3 days to 12 months (median ± SD; 4.6 ± 3.8) and in weight from 3.2 to 8.9 kg (4.6 ± 1.9) under TEE guidance by percutaneous or hybrid (perventricular) techniques. The size of the VSD as assessed by TEE ranged from 3 to 11 mm (6.0 ± 2.2) and the Qp:Qs ratio ranged from 0.7 to 8.8 (2.8 ± 2.3). Results: The device was successfully placed in 19/20 infants and it ranged in size from 4 to 14 mm (8.0 ± 2.6). It was percutaneously deployed in 11/19 and by the hybrid approach in 8/19. There were 30 devices placed in 19 infants with multiple devices placed in 5/19 infants. Fluoroscopy times ranged from 11 to 136 min (41 ± 28) and procedure times ranged from 57 to 291 min (178 ± 68). The success rate as defined by complete closure or a trivial shunt was 84% immediately and 100% at 1‐year follow‐up. Major complications occurred in 4/20 patients: wire perforation and hemopericardium (n = 1), device migration (n = 1), transient electromechanical dissociation (n = 1), and mediastinitis (n = 1). At a median follow‐up of 3.8 years, all patients improved and had no hemodynamically significant VSDs. No major complications were encountered in patients with multiple devices. Conclusion: In infants less than 1 year of age, percutaneous and perventricular device closure of mVSDs is technically feasible and highly effective with low morbidity. Long term safety and efficacy needs to be assessed.


  • Device Closure of Congenital Ventricular Septal Defects

    by Karim A. Diab, Qi-Ling Cao, Ziyad M. Hijazi

    Ventricular septal defect is the most common congenital heart malformation. Surgical closure, when indicated, has been practiced for over 50 years with good results; however, surgical closure is still associated with significant morbidity and mortality. Over the past decade, several occluding devices have been developed that made catheter device closure an attractive alternative to surgery with widely satisfactory results. In this article, a comprehensive review of percutaneous and perventricular (hybrid) device closure of each type of ventricular septal defect is presented.


  • Transcatheter Closure of Atrial Septal Defects in Adults ≥40 Years of Age: Immediate and Follow‐Up Results

    by Angira Patel, Keila Lopez, Anirban Banerjee, Annette Joseph, Qi‐Ling Cao, Ziyad M. Hijazi

    Background: Controversy still exists regarding closure of atrial septal defects (ASDs) in patients >40 years of age who are largely asymptomatic or do not have large shunts (LS). If left unrepaired, the majority of patients will experience symptoms and will have a shorter life span compared to patients who undergo repair. This study presents the outcomes of closure of ASDs in adults >40 years using the Amplatzer septal occluder. Methods: A total of 113 patients (79F/34M) with a mean age of 57.9 years (SD 11.9) who had indications for closure (right ventricular [RV] enlargement by echocardiograpy, clinically symptomatic) underwent an attempt of transcatheter closure. The mean size of ASD as measured by transesophageal echocardiography (TEE) (30 patients) or intracardiac echocardiography (83 patients) was 17.2 mm (SD 7.3) with mean Qp:Qs of 2.2:1 (SD 1.1). Follow‐up at 24 hours, 6 month, and yearly thereafter included physical examination, TEE, and/or transthoracic echocardiography; furthermore, chart review (n = 112) as well as telephone interviews (n = 56) were conducted to determine clinical symptomatic status. Results: The procedure was successful in 112 patients and 1 patient failed due to the presence of a large defect (44 mm). One hundred four patients had a single device implanted, 7 had two, and 1 had three. Following the procedure, 96 patients had immediate complete closure (CC), 3 had trivial shunt (TS), 11 had small shunt (SS), and 2 had moderate shunt (MS). At 24 hours postprocedure, 100 patients had CC, 7 had TS, 3 had SS, 1 had MS, and 1 had LS. Four patients had complications: one had device migration within 24 hours, two had atrial arrhythmias (supraventricular tachycardia, atrial tachycardia), and one had large hematoma. At 6 months postprocedure, 100 patients had CC, 6 had TS, 5 had SS, and 1 had MS. At 6‐month follow‐up, the right ventricle end‐diastolic dimension decreased from 35.3 mm (SD 7.6) preprocedure to 23.8 mm (SD 6.6) (P < 0.001) and the majority of patients reported improvement in their symptoms. Conclusions: ASD closure is safe and effective in patients over 40 years of age with minimal complications. The procedure resulted in a decrease in the RV size that was accompanied by improvement in clinical symptoms. Our findings suggest that device closure of ASDs in adult patients >40 years of age should be the first option of management.


  • Transcatheter closure of perimembranous ventricular septal defects using the amplatzer membranous VSD occluder: Immediate and midterm results of an international registry

    by Ralf Holzer, Jo de Giovanni, Kevin P. Walsh, Andrew Tometzki, Th Goh, Fakhri Hakim, Carlos Zabal, Jose Suarez de Lezo, Qi-Ling Cao, Ziyad M. Hijazi

    Objective: To report the immediate and midterm results of transcatheter closure of perimembranous ventricular septal defect (PmVSD) using the Amplatzer membranous VSD occluder (AMVSD). Methods: Between April 2002 and August 2004, 100 patients underwent an attempt of percutaneous device closure of PmVSD using the AMVSD in 24 international centers. The median age was 9.0 years (0.7–58 years) and the median weight was 27.5 kg (7–121 kg). Results: A device was successfully deployed in 93/100 (93%) patients. Reasons for procedural failure were an increased gradient across the left ventricle outflow tract in one patient, aortic regurgitation in 2 patients, and inability to securely position the device in 4 patients. The median VSD size by TEE was 7.0 mm (1.5–13 mm), median device size 10 mm (4–16 mm) and median fluoroscopy time 22.1 min (8.9–96.0 min). Weight below 10 kg (P = 0.0392), inlet extension of the VSD (P = 0.0139) and aortic cusp prolapse into the VSD (P = 0.0084) were significantly associated with a lower procedural success. Patients have been followed up for a median of 182 days (1–763 days). There were no procedure‐related deaths. Complications were encountered in 29/100 (29%) patients, including rhythm or conduction anomalies in 13 patients (two with complete heart block requiring permanent pacemaker implantation), new or increased aortic (9 patients) or tricuspid (9 patients) regurgitation, most of which were classified as trivial or mild. Patients with a weight below 10 kg had a significantly higher incidence of adverse events than patients with a weight above 10 kg (58.3% versus 25.0%, P = 0.0285). Immediately after device release complete closure of the defect was present in 54/93 (58.1%) patients, increasing to 46/55 (83.6%) patients at 6‐months follow‐up (P = 0.0012). Left ventricle end‐diastolic diameter decreased from a median of 44 mm prior to device closure to a median of 39 mm at 6‐months postprocedure (P = 0.0015). Conclusion: Closure of PmVSDs using the AMVSD occluder is safe and effective. However, longer follow‐up period is warranted prior to the wide spread use of this device.